Zivo Bioscience Reports No Revenue and Increased Losses in Latest Financial Filing

Zivo Bioscience, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending March 31, 2025. The company recorded no revenue during this period, a stark decline from $35,720 in the same quarter of the previous year. This drop is attributed to a lack of product orders from its exclusive distributor. The absence of revenue contributed to a net loss of $4.2 million, compared to a loss of $1.3 million in the prior year, marking a 229% increase in losses year-over-year. The basic and diluted loss per share also increased to $1.12 from $0.47.

The company's total expenses surged to $4.2 million for the quarter, up from $1.3 million in the same period last year. This increase was primarily driven by a substantial rise in research and development (R&D) costs, which reached approximately $2.8 million, compared to $312,767 in the previous year. The increase in R&D expenses was largely due to costs associated with extinguishing several outstanding Participation Agreements, which were not present in the prior year. General and administrative expenses also rose to $1.4 million, up from $975,000, largely due to increased professional fees.

Operationally, Zivo Bioscience has made strategic moves, including entering into fifteen Exchange Agreements with participants in its Participation Agreements, resulting in the issuance of 131,380 shares of common stock. This initiative is part of the company's strategy to manage its financial obligations and reduce liabilities. The company also moved its headquarters to a new facility in Troy, Michigan, and entered a lease for a laboratory and office space in Fort Myers, Florida, indicating a focus on expanding its operational capabilities.

As of March 31, 2025, Zivo Bioscience reported total assets of $1.3 million, down from $1.6 million at the end of the previous fiscal year. The company’s liabilities increased significantly to $2.9 million, compared to $2.2 million at the end of 2024, reflecting a growing financial burden. The company’s cash position has also deteriorated, with cash reserves dropping to $517,189 from $1.5 million at the end of the previous quarter. The company has expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for additional funding to sustain operations.

Looking ahead, Zivo Bioscience plans to continue its focus on R&D to develop bioactive compounds derived from its proprietary algal culture, targeting various health applications. However, the company acknowledges that it will require approximately $5 million in cash over the next 12 months to fund basic operations, excluding R&D initiatives. The management has indicated that without securing additional funding, the company may need to curtail its operations, including R&D activities, which could significantly impact its future prospects.